Philips Set to Showcase Ultrasound Compact 5500CV at ASE Conference


The new portable ultrasound device, which is being showcased at the American Society of Echocardiography (ASE) conference, offers enhanced cardiac imaging as well as shared transducer interoperability and workflows with existing EPIQ CVx and Affiniti CVx ultrasound systems.

The combination of increasing echocardiography volume and clinician shortages continue to require portable imaging options that can facilitate high quality and efficient ultrasound use at the patient bedside. With these issues in mind, Philips is slated to debut the Ultrasound Compact 5500CV device at the American Society of Echocardiography (ASE) conference this weekend.

One of the features of the Ultrasound Compact 5500CV device is AutoStrain, which provides two-dimensional strain quantification of the left ventricle through robust visualization and analysis, according to Philips.

The company said another benefit of the Ultrasound Compact 5500CV include three-hour battery life that facilitates longer scan times. Philips noted the Ultrasound Compact 5500CV also has transducer interoperability and shared workflow with other Philips ultrasound systems such as EPIQ CVx and Affiniti CVx.

“A key advantage of a portable system is the ability to bring the diagnostic power of echocardiography to (patients) wherever they are in an efficient manner. The image quality of the 5500CV allows us to use this advantage without compromising the certainty of the diagnosis,” noted David Liang, M.D., Ph.D, a professor at Stanford University and director of the Hoag Marfan Syndrome and Related Conditions Program at the Hoag Hospital in Newport Beach, Calif.

(Editor’s note: For related content, see “Pie Medical Imaging Launches AI-Powered Echocardiography Platform” and “Mindray Launches New Handheld Ultrasound Device.”)

Related Videos
Emerging Innovations in Molecular Imaging
Ultra-High Resolution Brain PET: A ‘Quantum Leap’ for Neuroradiology
Emerging PET Radiotracer May Improve Detection of Coronary Artery Disease in Obese Patients
Can SPECT/CT Guidance Facilitate Personalized Dosing for Patients with Prostate Cancer?
New Research Shows Viability of PET Imaging Agent for Clear Cell Renal Cell Carcinoma
A Closer Look at Urinary Activity and PET Radiopharmaceuticals for Prostate Cancer Imaging
Expediting the Management of Incidental Pulmonary Emboli on CT
Radiology Challenges with Breast Cancer Screening in Women with Breast Implants
Related Content
© 2023 MJH Life Sciences

All rights reserved.